PathAI builds artificial intelligence tools for pathology, helping doctors and researchers analyze tissue samples with greater accuracy and consistency. Pathology — the microscopic examination of tissue to diagnose diseases — has remained largely manual for over a century. PathAI is bringing that field into the computational age.
Their platform digitizes glass slides into high-resolution whole-slide images, then applies machine learning models trained on millions of annotated tissue samples. These models can detect patterns invisible to the human eye, quantify biomarkers with precision that manual counting can’t achieve, and flag areas of concern for pathologists to review. The AI doesn’t replace pathologists — it augments them with quantitative tools.
PathAI serves two main markets: clinical diagnostics and biopharma research. On the clinical side, their tools help pathology labs process cases faster and more consistently. On the biopharma side, they help drug companies design better clinical trials by identifying which patients are most likely to respond to specific treatments based on tissue characteristics.
The company has partnerships with major pharmaceutical companies including Bristol Myers Squibb, Novartis, and Roche for clinical trial pathology work. They’ve raised over $400 million in funding and employ a team that blends deep expertise in machine learning with board-certified pathologists. PathAI’s technology addresses a critical bottleneck in healthcare — there’s a growing global shortage of pathologists even as the demand for tissue-based diagnostics continues rising.
